AB-101
Chronic Hepatitis B (cHBV)
Phase 2Active
Key Facts
About Arbutus Biopharma
Arbutus Biopharma is a pure-play virology company with a mission to achieve a functional cure for chronic hepatitis B (HBV). Its core strategy is a multi-mechanistic combination approach, anchored by its RNAi therapeutic imdusiran, which has demonstrated meaningful functional cure rates in clinical trials. The company is led by a newly appointed, transaction-savvy leadership team with deep expertise in building and scaling biotech ventures. Arbutus's concentrated focus on the large, underserved HBV market positions it as a key contender in the race for a curative regimen.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B (cHBV) Drugs
| Drug | Company | Phase |
|---|---|---|
| Imdusiran (AB-729) | Arbutus Biopharma | Phase 2 |
| Combination Regimens (Imdusiran-based) | Arbutus Biopharma | Phase 2 |
| AB-161 | Arbutus Biopharma | Phase 1 |